Baltimore's 38.1% obesity rate, a COMAR regulation excluding weight-control drugs from Medicaid, ten-plus active HPSAs across the city's low-income geography, and no verifiable local self-pay price.
Baltimore's adult obesity prevalence is 38.1% (CDC PLACES 2025 release, BRFSS 2023) 1 against Maryland's statewide 34.1% for the same year 2. This independent city of 573,243, county-equivalent and distinct from the separate Baltimore County, sits inside a 2,849,436-person metro with a 6.6% uninsured rate and a $64,778 median household income 3456.
Two things follow, and neither is a marketing line: Maryland Medicaid excludes these drugs for weight control by regulation, and no Baltimore clinic found in this pass publishes what treatment costs.
Maryland Medicaid's fee-for-service pharmacy benefit explicitly excludes semaglutide and tirzepatide when prescribed for weight control. The state's own regulation, COMAR 10.09.03.05.A(14), excludes "oral drugs or injections for central nervous system stimulants, anorexigenics, and any other agents when used for weight control" 10. That is Maryland exercising an optional federal exclusion category under Social Security Act §1927(d)(2)(A) that not every state opts into.
The same drugs remain covered as antidiabetic agents for type 2 diabetes, a different indication unaffected by the exclusion 10. KFF's 50-State Medicaid Budget Survey for FY2023 to 2024 corroborates it: sixteen states covered at least one weight-loss medication as of July 2023, and Maryland is not among them 11. Individual HealthChoice MCO formularies, including Aetna Better Health of Maryland, Priority Partners, and Maryland Physicians Care, can in principle add supplemental benefits beyond that baseline; those plan-level formularies were not checked, so this is not ruled out.
An extensive search this pass could not find an independent Baltimore-city clinic publishing its own self-pay semaglutide or tirzepatide price online. Checked and ruled out: Medi-Weightloss (no Maryland location in its directory), Sōna MedSpa (North Carolina and Virginia only), RenewMD Wellness (California only), NueBody (site returned no content), and Ideal Image (site unreachable). Mercy Medical Center's and MedStar Union Memorial Hospital's weight-management pages could not be located at their expected URLs.
The University of Maryland Midtown "GLP-1 Clinic," led by Dr. Munir and reported in Baltimore Magazine, appears to be a real academic obesity-medicine program, but its site blocked automated access and, as a hospital referral program, very likely bills through insurance rather than posting a cash price. This is an open data gap, not proof that no priced clinic exists in Baltimore, and it deserves a manual follow-up before anyone treats "price-opaque" as settled.
What is verifiable is Astra's own number. Astra's price is published and flat everywhere it treats: $68/month for compounded semaglutide and $118/month for compounded tirzepatide, both on 12-month plans billed annually at $816 and $1,416. That is the same number in Baltimore as in every other state Astra serves, with no local rate and no consult required to see it.
Baltimore City carries at least ten distinct active Low-Income-Population and High-Needs Geographic Primary Care HPSAs: West Baltimore City and West Central Baltimore City (each score 17, populations 13,898 and 155,501), Pimlico/Park Heights/Falstaff (score 21, 22.7% below poverty), Greater Charles Village/Lower Guilford (score 21), East Central and North Central Baltimore City (scores 21 to 22, poverty 29.5% to 31.4%), Southern Baltimore City (score 22, 31.1% poverty), East and Southeast Baltimore City (score 21), Parks Run (score 16), and North Baltimore (score 14), most redesignated in April and May 2026 7. Five FQHCs serving the city, Baltimore Medical System, Total Health Care, Park West Health Systems, Health Care for the Homeless, and Chase Brexton, hold their own designations at scores of 22 to 24 7. Mental Health HPSAs mirror the same geography 89.
That coexists with two academic systems, Johns Hopkins Medicine and the University of Maryland Medical System, which runs the Midtown GLP-1 Clinic under Dr. Munir. In aggregate Baltimore has some of the highest endocrinology and obesity-medicine density in Maryland, concentrated at a handful of downtown and East Baltimore campuses and largely insurance-referral-gated rather than direct-access.
The shortage geography sits in West and Southwest Baltimore, Pimlico and Park Heights, West Central, Southern Baltimore City, often several miles and multiple bus transfers from those campuses, in neighborhoods with 20 to 40%-plus poverty 7. Real access here depends on which side of the city you live on and whether you can get a referral. A directly accessible telehealth prescriber closes that gap evenly across neighborhoods. Astra is available to Baltimore residents the same as anywhere else, in all 50 states.
Astra treats patients in Maryland through state-licensed physicians.
We could not find an independent Baltimore clinic — including Medi-Weightloss, Ideal Image, or the University of Maryland Midtown GLP-1 Clinic — that publishes its own self-pay price online. What is public is Astra's price: $68/month for semaglutide and $118/month for tirzepatide, both on 12-month plans ($816 and $1,416 billed annually), the same in Baltimore as everywhere else Astra serves.
We can't give Baltimore a fair price comparison, because no local clinic we checked publishes a self-pay semaglutide or tirzepatide price. What we can say plainly: Astra's price isn't a city-specific rate — it's $68/month for semaglutide and $118/month for tirzepatide on a 12-month plan, identical in Baltimore, across Maryland, and in every other state Astra serves.
No — Maryland Medicaid's fee-for-service pharmacy benefit specifically excludes GLP-1s like semaglutide and tirzepatide when prescribed for weight control (COMAR 10.09.03.05.A(14)). The same drugs are covered when prescribed for type 2 diabetes, a different indication. Individual HealthChoice managed-care plans can in principle offer supplemental benefits beyond that baseline — check directly with your specific MCO.
Baltimore City's adult obesity rate is 38.1% (crude prevalence, 2023 BRFSS data via the CDC's 2025 PLACES release) — above Maryland's 34.1% statewide rate for that same 2023 data year. Using Maryland's more recent 2024 BRFSS figure, the state rate has since eased to 32.7%, which widens rather than narrows the gap between the city and the state overall.
It's split by neighborhood. Baltimore has some of Maryland's densest endocrinology/obesity-medicine expertise, anchored by Johns Hopkins and the University of Maryland Medical System's GLP-1 Clinic — but HRSA designates large parts of the city, especially West Baltimore, West Central Baltimore, and Pimlico/Park Heights, as active Primary Care and Mental Health shortage areas, several redesignated as recently as April–May 2026. Access in practice depends heavily on which side of the city you live on and whether you have an insurance referral — a gap a telehealth prescriber can close evenly, regardless of neighborhood.
Last reviewed:
Educational information, not medical advice. Treatment requires evaluation by a licensed physician.